Association between rs1801133 polymorphism and risk of adult ischemic stroke: Meta-analysis based on case-control
Min Chen1, Ben Yu Mao1, Dan Wang1
1The First Hospital of Jing Zhou, Yangtze University, Hangkong street 8, Jingzhou 434000, Hubei, China.
Background:
This study is aimed to quantify the strength of the association between rs1801133 polymorphism and ischemic stroke risk.
Methods:
We have searched Medline, Springer, and Embase for studies investigating the association between rs1801133 polymorphism and ischemic stroke risk. We estimated the pooled odds ratio with its 95% confidence intervals to assess this possible association.
Results:
Forty case-control studies comprising 8809 cases and 9130 controls are eligible for this meta-analysis on the basis of relation of rs1801133 polymorphism to ischemic stroke risk. Hardy-Weinberg equilibrium was used to perform in controls for excluding articles. The overall analysis suggested that rs1801133 polymorphism was associated with increased risk of ischemic stroke (ORT versus C=1.16, 95% CI 1.10-1.22; ORTT versus TC+CC=1.32, 95% CI 1.18-1.47; ORTT+TC versus CC=1.11, 95% CI 1.04-1.18). Subgroup analysis showed that T allele was a significant strength between T allele and stroke risk in Asian, Caucasian, male and young-middle populations (OR=1.19, 1.11, 1.30, 1.16, respectively). Compared with TC+CC, TT genotype was found to be a risk factor for developing ischemic stroke in Asian, Caucasian and male (OR=1.41, 1.20, 1.77, respectively). Additionally, TT+TC retained a significant increase for ischemic stroke only in Asian comparable to CC genotype (OR=1.14).
Conclusions:
The rs1801133 polymorphism could be capable of increasing ischemic stroke susceptibility in Asian, male and young-middle populations.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Single Nucleotide Polymorphisms-SNPs
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Atherosclerosis III: Management
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase


